Vizora日本語

Morishita JintanMORISHITA JINTAN CO.,LTD.4524東証スタンダード医薬品FY ending Mar 2026, consolidated, J-GAAP

Morishita Jintan FY ending Mar 2024 results

About 34% of Morishita Jintan's sales come from Healthcare business division, with Solution business division and Consumer business division making up much of the rest.

Out of every ¥100 of sales, about ¥6 is left as operating profit.

Revenue changed +9.2% from the prior year, operating profit +25.8%.

Revenue and profit pattern

Revenue and profit upProfit grew faster

Revenue +9.2% · profit +25.8%, calculated from disclosed figures.

Operating leverage: 2.80× (profit growth ÷ revenue growth)

What changed from last year

FY ending Mar 2023 → FY ending Mar 2024

Revenue
+9.2%¥11.4B → ¥12.4B
Gross profit
+12.9%¥5.31B → ¥6B
Operating income
+25.8%¥569M → ¥716M
Net income attributable to owners
+42.0%¥491M → ¥697M
Operating cash flow
-83.4%¥1.18B → ¥196M
Free cash flow
-163.6%¥715M → -¥455M

Where the money goes

FY ending Mar 2023 → FY ending Mar 2024

※ Segment revenues include inter-segment sales and are scaled to consolidated revenue

Where ¥100 of sales goes

For every ¥100 Morishita Jintan sells, how much goes where, and how much is kept.

FY ending Mar 2024
Cost of sales
¥52
SG&A
¥42
Operating profit
¥6
Net profit kept
¥6

Annual margin trends

Gross margin48.3%
FY ending Mar 2020: 53.0%53.0%FY ending Mar 2021: 50.8%50.8%FY ending Mar 2022: 51.0%51.0%FY ending Mar 2023: 46.8%46.8%FY ending Mar 2024: 48.3%48.3%FY20FY21FY22FY23FY24
Operating margin5.8%
FY ending Mar 2020: 4.6%4.6%FY ending Mar 2021: 2.4%2.4%FY ending Mar 2022: 3.1%3.1%FY ending Mar 2023: 5.0%5.0%FY ending Mar 2024: 5.8%5.8%FY20FY21FY22FY23FY24
Net margin5.6%
FY ending Mar 2020: 3.3%3.3%FY ending Mar 2021: 2.2%2.2%FY ending Mar 2022: 3.0%3.0%FY ending Mar 2023: 4.3%4.3%FY ending Mar 2024: 5.6%5.6%FY20FY21FY22FY23FY24

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Which businesses earn the money

Revenue by business segment, and the profit each one keeps.

FY ending Mar 2024
  • Healthcare business division¥8.35B
    34%
    Op. margin -5.5%
  • Solution business division¥6.95B
    28%
    Op. margin 7.5%Industry: CRO & Clinical Testing
  • Consumer business division¥5.45B
    22%
    Op. margin 3.3%Industry: Processed Foods
  • Capsule contract manufacturing business division¥4.05B
    16%
    Op. margin 28.7%
  • Other¥9M
    0%
    Op. margin 100.0%

Profit by segment

※ Segment figures include inter-segment sales and do not sum to the company total

Sources

Show source documents (6)

  • EDINET (FSA Japan)

    有価証券報告書－第89期(2025/04/01－2026/03/31)

    ID S100YE3I2026-06-22Open

  • EDINET (FSA Japan)

    有価証券報告書－第88期(2024/04/01－2025/03/31)

    ID S100W0BR2025-06-20Open

  • EDINET (FSA Japan)

    有価証券報告書－第87期(2023/04/01－2024/03/31)

    ID S100TRZ72024-06-26Open

  • EDINET (FSA Japan)

    有価証券報告書－第86期(2022/04/01－2023/03/31)

    ID S100R8RC2023-06-29Open

  • EDINET (FSA Japan)

    有価証券報告書－第85期(令和3年4月1日－令和4年3月31日)

    ID S100OJ6V2022-06-29Open

  • EDINET (FSA Japan)

    有価証券報告書－第84期(令和2年4月1日－令和3年3月31日)

    ID S100LOVX2021-06-29Open

Extracted from XBRL: 48 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open MarkdownShare on XSave image